References
- Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159. doi: 10.1016/j.jacc.2007.01.091.10.1016/j.jacc.2007.01.09117543634
- Konstam MA, Gheorghiade M, Burnett JCJ, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331. doi: 10.1001/jama.297.12.1319.10.1001/jama.297.12.131917384437
- Tavare AN, Murray D. Central pontine myelinolysis. N Engl J Med. 2016;374:e8. doi: 10.1056/NEJMicm1504134.10.1056/NEJMicm150413426886548
- Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188-195. doi: 10.1016/j.ejheart.2008.01.011.10.1016/j.ejheart.2008.01.01118279773
- Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988. doi: 10.1093/eurheartj/ehl542.10.1093/eurheartj/ehl54217309900
- Takeda M, Takada T, Satake H, Sugeno M, Kanemitsu H, Shiba N. Efficacy and safety of tolvaptan administration from nasogastric tube in patients under mechanical ventilation with severe congestive heart failure [in Japanese]. Shinzo. 2016;48:1033-1041. doi: 10.11281/shinzo.48.1033.
- McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med. 1971;285:1441-1446. doi: 10.1056/NEJM197112232852601.10.1056/NEJM1971122328526015122894
- JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J. 2013;77:2157–2201. doi: 10.1253/circj.cj-66-0068.10.1253/circj.CJ-66-0068
- Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
- Matsue Y, Suzuki M, Torii S, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail. 2016;22:423-432. doi: 10.1016/j. cardfail.2016.02.007.
- Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696. doi: 10.1161/01. CIR.0000070422.41439.04.
- Kinugawa K, Sato N, Inomata T, Yasuda M, Shimakawa T, Fukuta Y. Real-world effectiveness and tolerability of tolvaptan in patients with heart failure – final results of the Samsca post-Marketing surveillance In heart faiLurE (SMILE) Study. Circ J. 2019;83:1520-1527. doi: 10.1253/circj.CJ-19-0158.10.1253/circj.CJ-19-015831118355
- Darmon M, Timsit JF, Francais A, et al. Association between hypernatraemia acquired in the ICU and mortality: a cohort study. Nephrol Dial Transplant. 2010;25:2510-2515. doi: 10.1093/ndt/gfq067.10.1093/ndt/gfq06720167570
- Abdel-Qadir HM, Tu J V, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010;160:264-271. doi: 10.1016/j.ahj.2010.05.032.10.1016/j.ahj.2010.05.03220691831
- Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764. doi: 10.1016/j.amjcard.2005.12.072.10.1016/j.amjcard.2005.12.07216765130
- Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338. doi: 10.1016/j.ahj.2003.08.012.10.1016/j.ahj.2003.08.01214760333
- Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805. doi: 10.1056/NEJMoa1005419.10.1056/NEJMoa1005419341235621366472
- Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729. doi: 10.1161/01.cir.82.5.1724.10.1161/01.CIR.82.5.17242146040
- Nakada Y, Takahama H, Kanzaki H, et al. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure. Heart Vessels. 2016;31:925-931. doi: 10.1007/s00380-015-0688-7.10.1007/s00380-015-0688-725964073
- Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-278. doi: 10.1152/ajprenal.00195.2005.10.1152/ajprenal.00195.2005264714016189291
- Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels. 2016;31:1650-1658. doi: 10.1007/s00380-015-0780-z.10.1007/s00380-015-0780-z26676672
- Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399-405. doi: 10.1016/j.jjcc.2015.09.020.10.1016/j.jjcc.2015.09.02026692119
- Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc Drugs Ther. 2011;25:S33-S45. doi: 10.1007/s10557-011-6304-x.10.1007/s10557-011-6304-x22120092
- Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment – results from the K-STAR study. Circ J. 2017;82:159-167. doi: 10.1253/circj.CJ-17-0179.10.1253/circj.CJ-17-017928835586